Start with the pathology report, whether surgery is possible, exact prior treatments and your molecular results. First-line, maintenance, post-progression and after-surgery studies have different requirements.
Answer a few questions to find clinical trials matched to your specific Pancreatic Cancer situation.
A thorough search takes ~15 minutes — we'll email your results. No sign-up.
🎉 FDA APPROVAL (August 26, 2026): The FDA approved daraxonrasib (RASONQUE) for adults with metastatic pancreatic adenocarcinoma who have had ≥1 prior systemic therapy or are not candidates for multiagent chemotherapy — the first RAS-targeted therapy ever approved for pancreatic cancer. Basis: the pivotal Phase 3 RASolute 302 (NCT06625320, previously-treated metastatic PDAC, n=500), which showed median overall survival 13.2 vs 6.7 months (HR 0.40, p<0.0001) — a 60% reduction in the risk of death, PFS 7.2 vs 3.6 months, ORR 30% vs 11%. Recommended dose 300 mg orally once daily. These group results do not predict an individual outcome. The recruiting Revolution Medicines RAS(ON) PDAC trials (below) test daraxonrasib in earlier settings — 1L metastatic and adjuvant.
🔔 Post-ASCO 2026 (May 29 – June 2) update: KRAS-directed studies are an important part of pancreatic cancer research. Three new KRAS G12D Phase 3 trials launched in July 2026: NCT07621718zoldonrasib (RMC-9805) + chemo 1L metastatic, NCT07522073INCB161734 + chemo 1L KRAS G12D, and NCT07409272setidegrasib (ASP3082) KRAS G12D degrader + mFOLFIRINOX/NALIRIFOX. The daraxonrasib (RMC-6236, pan-RAS(ON)) Phase 3 PDAC program — RASolute 303 NCT07491445 (1L metastatic) and RASolute 304 NCT07252232 (resected adjuvant) — is being studied in earlier treatment settings. Two more new entrants: NCT07562152 atebimetinib + GnP (MEK), NCT07490301telisotuzumab adizutecan + FOLFOX (c-MET ADC). Cross-link: KRAS Inhibitors hub for the cross-cancer view; CLDN18.2 hub for the CLDN18.2 ADC + CAR-T landscape.
Current Clinical Trial Landscape
Active research areas in 2026:
KRAS-targeted therapies — pan-RAS inhibitors (daraxonrasib/RMC-6236 now in both first-line metastatic and adjuvant resected Phase 3), G12D-specific (RMC-9805, HRS-4642), G12C inhibitors (sotorasib), G12V TCR-T cell therapy, KRAS neoantigen vaccines
BRCA/PALB2-directed — platinum-based regimens, PARP inhibitors (olaparib (Lynparza) — POLO trial maintenance landmark), separate from niraparib/ipilimumab maintenance research (NCT06747845), which excludes several HR-repair alterations including BRCA1/2 and PALB2; homologous recombination deficiency-guided therapy. See the PARP Inhibitors mechanism hub.
Standard of care: For resectable disease: surgery followed by adjuvant modified FOLFIRINOX (6 months) or gemcitabine + capecitabine. Neoadjuvant chemotherapy increasingly used for borderline resectable. For locally advanced: FOLFIRINOX or gemcitabine/nab-paclitaxel, with radiation in selected cases. For metastatic: NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/leucovorin; FDA first-line approval Feb 2024), FOLFIRINOX (fit patients) or gemcitabine/nab-paclitaxel. For the rare NRG1 fusion-positive tumors, zenocutuzumab (Bizengri) after prior therapy (accelerated approval Dec 2024). Olaparib maintenance for germline BRCA1/2-mutated metastatic disease without progression after at least 16 weeks of first-line platinum treatment (POLO); PALB2 alone does not establish this approved indication. Second-line: daraxonrasib (FDA Aug 26, 2026, RASolute 302; after ≥1 prior systemic therapy) or nanoliposomal irinotecan + 5-FU/leucovorin (NAPOLI-1).
Key Biomarkers for Trial Eligibility
Ask the treating team about germline testing and tumor molecular profiling; a molecular finding alone does not establish treatment or trial eligibility:
KRAS mutation type — present in ~90% of PDAC. The specific variant matters for targeted therapy:
KRAS G12D (~40%) — most common; RMC-9805, HRS-4642 trials
KRAS G12V (~30%) — G12V-selective RMC-5127, pan-KRAS inhibitors, and HLA-matched TCR-T cell therapy (see G12V trials)
KRAS G12C (~1-2%) — sotorasib (FDA-approved for NSCLC, trials in PDAC)
KRAS G12R (~15%) — pan-RAS(ON) inhibitors such as daraxonrasib; several pan-KRAS trials exclude G12R (see G12R trials)
BRCA1/2 or PALB2 mutation — germline mutations in ~5-7%. May inform platinum treatment and trial selection. Approved pancreatic olaparib maintenance requires germline BRCA1/2-mutated metastatic disease without progression after at least 16 weeks of first-line platinum; PALB2 alone is not that indication.
MSI-H / dMMR — rare (~1-2%) may support pembrolizumab for qualifying unresectable/metastatic solid tumors after prior treatment when satisfactory alternatives are absent; full label criteria apply.
Claudin 18.2 (CLDN18.2) expression — expressed in ~60% of PDAC. Target for IBI343 ADC (Phase 3) and CAR-T therapy.
NTRK fusion — very rare (<1%) but druggable with larotrectinib or entrectinib (FDA-approved).
HER2 amplification — rare (~2-3%) may support HER2-directed trials. HER2 amplification alone does not establish the tumor-agnostic T-DXd indication, which requires IHC 3+ and additional clinical criteria.
ctDNA (circulating tumor DNA) — increasingly used to guide adjuvant therapy decisions. Several trials use ctDNA to identify patients who may benefit from additional treatment after surgery.
Know your KRAS variant and BRCA status? Get matched to pancreatic cancer trials in minutes.
FOLFIRINOX or gemcitabine/nab-paclitaxel remain standard. Trials add novel agents:
Pan-RAS / KRAS-directed first-line:
NCT07491445 - RASolute 303: Daraxonrasib (RMC-6236) monotherapy and daraxonrasib + Gemcitabine/Nab-paclitaxel vs SOC in first-line metastatic PDAC (Phase 3, the registrational metastatic-setting trial of the pan-RAS(ON) inhibitor)
NCT07562152 - Atebimetinib + Gemcitabine/Nab-paclitaxel as first-line treatment in metastatic PDAC (Phase 3 MEK inhibitor combo)
NCT06095141 - Cisplatin for PDAC with homologous recombination deficiency (Phase 2/3)
Additional selected recruiting studies
NCT06752811 — Polymeric micellar paclitaxel plus gemcitabine versus nab-paclitaxel/gemcitabine for previously untreated metastatic pancreatic cancer (Phase 3).
NCT07238283 — Liposomal irinotecan formulation plus oxaliplatin/5-FU/leucovorin versus nab-paclitaxel/gemcitabine in previously untreated metastatic disease (Phase 3).
NCT06593431 — EXPAND: metastasis-directed treatment for selected patients with one to five distant lesions; all disease sites must be suitable for local treatment, so this is not a general option for widespread metastases (Phase 3).
NCT06332274 — UMBRELLA: ctDNA-guided tislelizumab or follow-up strategies after curative-intent treatment for selected cancers, including stage I–III pancreatic cancer; MRD-positive and MRD-negative groups differ (Phase 3).
First-line maintenance research
Maintenance is a strategy after initial treatment control, not treatment after progression.
NCT06747845 — Niraparib plus ipilimumab maintenance after 4–6 months of first-line FOLFIRINOX or NALIRIFOX with stable disease or better. Excludes known pathogenic BRCA1/2, PALB2, RAD51C or RAD51D alterations and prior PARP/CTLA-4 inhibitors (Phase 2)
Second-Line / Pretreated
NCT07066098 - G-HOPE-002: IBI343 (Claudin 18.2 ADC) vs Placebo in CLDN18.2+ pretreated PDAC (Phase 3)
NCT01954992 - Glufosfamide vs 5-FU in second-line metastatic PDAC (Phase 3)
NCT06998940 - Chemotherapy with or without panitumumab after one prior cytotoxic line for unresectable/metastatic PDAC with tissue-confirmed KRAS and BRAF V600E wild type; other molecular restrictions apply (Phase 3)
NCT07436741 — Surufatinib plus gemcitabine/nab-paclitaxel before surgery for high-risk resectable or borderline-resectable pancreatic cancer; excludes distant metastases and BRCA1/2 or PALB2 mutations (Phase 3)
NCT06714604 - Standard vs prolonged neoadjuvant chemo before surgery for BR/LAPC (Phase 3)
NCT05529940 - NeoFOL-R: Perioperative vs adjuvant FOLFIRINOX in resectable PDAC (Phase 3)
NCT05268692 - Neoadjuvant chemo followed by GS and GnP (Phase 2/3)
NCT07081360 - Neoadjuvant vs upfront surgery for resectable PDAC (Phase 3)
Adjuvant:
NCT07252232 - RASolute 304: Daraxonrasib (RMC-6236, pan-RAS(ON)) vs SOC observation in resected PDAC (Phase 3)
NCT07044453 - Risk-adapted adjuvant chemo guided by tumor stage after neoadjuvant (Phase 2/3)
NCT06427447 - ADJUPANC: Adjuvant chemoradiotherapy vs chemo for PDAC (Phase 3)
NCT07632118 - Radiotherapy + GX regimen as adjuvant therapy for high-risk patients after pancreatic cancer surgery (Phase 3, activated 2026-06-09 — RT + gemcitabine/capecitabine (GX) intensification for high-recurrence-risk resected PDAC; positive-margin / node-positive / high-CA19-9 population)
NCT06250972 - Radiotherapy for CA19-9-elevated advanced PDAC (Phase 3)
KRAS-Targeted Therapies
Over 90% of pancreatic cancers have KRAS mutations. Once considered undruggable, KRAS is being tested in several Phase 3 PDAC studies: daraxonrasib (RMC-6236, pan-RAS(ON)) in both 1L metastatic and adjuvant-resected Phase 3; zoldonrasib (RMC-9805) and INCB161734 KRAS G12D RAS(ON) Phase 3; setidegrasib (ASP3082) KRAS G12D degrader Phase 3; HRS-4642 G12D for borderline resectable; HLA-matched KRAS G12V TCR-T (NCT04146298). For the cross-cancer KRAS class (sotorasib + adagrasib + calderasib + olomorasib + glecirasib + garsorasib in NSCLC + CRC), see the KRAS Inhibitors hub.
NCT05379985 - RMC-6236 in advanced solid tumors with RAS mutations (Phase 1/2)
KRAS G12D-specific studies:
NCT07621718 - Zoldonrasib (RMC-9805) + chemo vs Placebo + chemo as first-line treatment in metastatic PDAC with KRAS G12D (Phase 3, the first KRAS G12D RAS(ON) Phase 3 in PDAC)
NCT07805954 - Zoldonrasib (RMC-9805) + Daraxonrasib (RMC-6236) vs Gemcitabine/Nab-paclitaxel in metastatic PDAC (Phase 3, the first RAS(ON) doublet — G12D-selective + pan-RAS combination)
NCT07232875 - HRS-4642 + Gemcitabine/Nab-paclitaxel (AG) vs Placebo + AG in first-line advanced KRAS G12D PDAC (Phase 3)
KRAS G12R and G12V Pancreatic Cancer: Which Trials Accept Your Variant
Most new KRAS drugs in pancreatic cancer target G12D. If your tumor carries KRAS G12R or KRAS G12V, check each trial's list of allowed mutations: the newer "pan-KRAS" inhibitors do not all cover every variant. The trials below were checked against their published registry criteria on November 17, 2026. The trial team must confirm eligibility and cohort availability.
KRAS G12R (~15% of PDAC)
G12R is common in pancreatic cancer but rare elsewhere, so few trials are built for it. Two pan-KRAS inhibitor trials list their allowed mutations without G12R: BBO-11818 (NCT06917079) and BLU-924 / SAR449336 (NCT07629960). Studies whose published molecular criteria can include G12R; other entry criteria and cohort availability still apply:
Approved US treatment in a defined setting:daraxonrasib (RASONQUE), FDA-approved August 26, 2026 for metastatic pancreatic adenocarcinoma after ≥1 prior systemic therapy (or when multiagent therapy is not an option). It binds RAS in its active state across G12X variants, including G12R.
Pan-RAS options: daraxonrasib (approved after ≥1 prior therapy) and the pan-RAS trials listed under G12R above may cover G12V, subject to the specific cohort and other criteria.
TCR-T cell therapy (requires a matching HLA type):
NCT04146298 - RAS G12V-specific TCR-T for advanced pancreatic cancer; HLA-A*11:01 and prior-treatment requirements apply (Phase 1/2)
NCT06043713 - High-affinity KRAS G12V TCR-T cells for NSCLC, pancreatic and other cancers (Phase 1)
NCT07145450 - Master protocol of TCR-T therapies matched to mutant KRAS and HLA genotype in PDAC (Phase 1/2)
NCT06898385 - IX001 TCR-T for advanced pancreatic cancer with KRAS G12V (Phase 1)
NCT07649928 - ES502 for advanced RAS G12V pancreatic cancer with no remaining standard options; HLA-DPB1 typing required (Phase Early 1)
Claudin 18.2-targeted: IBI343 (ADC, G-HOPE-002 Phase 3), dual-target CAR-T (mesothelin + CLDN18.2), NCT07066995. For the cross-cancer CLDN18.2 landscape (zolbetuximab gastric SPOTLIGHT/GLOW, CT041 CAR-T, AZD0901, sonesitatug vedotin), see the CLDN18.2 hub.
c-MET ADC (new Phase 2/3 entry):NCT07490301 - Telisotuzumab Adizutecan + FOLFOX in metastatic PDAC (Phase 2/3, c-MET-directed ADC class entering PDAC)
HER2-targeted (HER2-amplified PDAC):trastuzumab deruxtecan (T-DXd) pan-tumor HER2 ADC program; HER2 amplification and IHC expression are different tests. Tumor-agnostic T-DXd approval requires IHC 3+, unresectable/metastatic disease, prior systemic therapy and no satisfactory alternative; individual trials use their own criteria. See the HER2 ADCs hub for cross-cancer ADC landscape.
Tumor treating fields:NCT05653453 - TTFields plus gemcitabine/nab-paclitaxel as first-line treatment for locally advanced pancreatic cancer (Phase 3)
Cancer cachexia (supportive care):NCT06989437 - Ponsegromab (GDF-15 antagonist) in PDAC patients with cachexia (Phase 2/3) — first dedicated cachexia Phase 2/3 for PDAC
ctDNA-guided:NCT05482516 - Novel therapies in ctDNA-positive GI cancers (active — not recruiting)
Intra-arterial chemotherapy: Direct hepatic artery or tumor infusion to overcome poor drug delivery in PDAC
A November 17 registry search for pancreatic cancer, recruiting interventional studies returned 667 records, including 59 with a Phase 3 component. This broad query includes supportive care, imaging, basket trials and other pancreatic tumor types; it is not a count of PDAC treatment options. Selected studies; overall recruitment is not proof of a local enrollment slot. Three cited studies are active, not recruiting (NCT03257033, NCT05482516 and historical RASolute 302 NCT06625320); HRS-2329 NCT07736612 is not yet recruiting. Status checked November 17, 2026. Search current recruiting interventional trials on ClinicalTrials.gov.
How do I find pancreatic cancer clinical trials I'm eligible for?
Enter your pancreatic cancer details into ClinTrialFinder — including KRAS mutation type (G12D, G12V, G12C, G12R), BRCA/PALB2 status, disease stage (resectable, borderline, locally advanced, metastatic), and prior treatments. The AI matches you with trials based on your specific profile in minutes. No login required.
What pancreatic cancer trials are currently recruiting?
Research includes RAS/KRAS inhibitors, CLDN18.2-directed treatments, chemotherapy combinations, cell therapies and maintenance studies. Check the dated selected-study listings and current registry search; first-line, post-progression, maintenance and after-surgery cohorts are different. Overall recruiting status does not guarantee a slot at your preferred hospital.
Should I get molecular profiling for pancreatic cancer?
Discuss germline testing and tumor molecular profiling with your treating team. KRAS variant, BRCA1/2 or PALB2, MSI/MMR, NTRK and HER2 testing may guide options. Approved pancreatic olaparib maintenance requires germline BRCA1/2-mutated metastatic disease without progression after at least 16 weeks of first-line platinum. PALB2 alone does not establish that indication; tumor-agnostic T-DXd requires HER2 IHC 3+ plus other clinical criteria.
Are KRAS-mutant pancreatic cancers now treatable with targeted therapy?
In the US, daraxonrasib is approved for adults with metastatic pancreatic adenocarcinoma after at least one prior systemic therapy or when multiagent systemic therapy is unsuitable. Earlier-stage and first-line combinations remain distinct research settings. KRAS G12D/G12V-selective agents, vaccines and TCR-T therapies have protocol-specific molecular, HLA and prior-treatment criteria.
Are there clinical trials for KRAS G12R pancreatic cancer?
Yes, but fewer than for G12D. Daraxonrasib (RASONQUE), a pan-RAS(ON) inhibitor that covers G12R, was FDA-approved in August 2026 for metastatic pancreatic cancer after at least one prior therapy. Trials that accept G12R include daraxonrasib's RASolute 303 (first-line, NCT07491445) and RASolute 304 (after surgery, NCT07252232), ASP5834 (NCT07094204), PT0511 (NCT07300150), and the ELI-002 7P KRAS vaccine for resectable disease (NCT07671339). Some pan-KRAS inhibitor trials, such as BBO-11818 and BLU-924, do not list G12R, so check each trial's allowed mutations.
What clinical trials are there for KRAS G12V pancreatic cancer?
Potential studies include RMC-5127, selected pan-KRAS/pan-RAS trials and HLA-matched TCR-T therapies. G12V alone does not establish eligibility. JAB-23E73 combination study NCT07640295 is Phase 1/2, first-line metastatic PDAC and excludes prior KRAS/RAS inhibitors. TCR study NCT04146298 requires HLA-A*11:01 and specified prior treatment.
Find Pancreatic Cancer Trials Matched to Your Situation
Enter your KRAS mutation type, BRCA status, and disease stage to get AI-matched trial results in minutes.
This page is for information only and is not medical advice. ClinTrialFinder helps you find clinical trials that may match your situation, but enrollment decisions and treatment choices should always be made with your oncologist or healthcare team. Trial eligibility, recruitment status, and treatment details can change — verify directly with the trial sponsor or on ClinicalTrials.gov before acting on any information here.